Innate Pharma Doses First Patient In IPH4502 Cancer Therapy Trial

Innate Pharma has initiated a Phase 1 clinical trial for IPH4502, a groundbreaking antibody-drug conjugate (ADC) targeting advanced solid tumors with high Nectin-4 protein levels. These proteins are frequently found in cancers such as bladder, breast, lung, and gastrointestinal tumors. The trial aims to explore the safety and efficacy of IPH4502 in patients who have limited treatment options and often face relapses.

Dr. Shiraj Sen, Medical Oncologist and Phase 1 Investigator at NEXT Oncology-Dallas, expressed optimism about the study, noting that IPH4502 is designed to address both high and low Nectin-4 expression, potentially improving outcomes for these challenging cases. Chief Medical Officer Dr. Sonia Quaratino emphasized the significance of advancing ADC technology within Innate Pharma's pipeline. The trial, enrolling approximately 105 patients, will involve two parts: determining the optimal dose and evaluating therapeutic effects, marking a crucial step toward providing innovative care for patients with advanced solid tumors.